Clinical-stage biopharmaceutical company developing therapies for cancer.
Mural Oncology plc is a clinical-stage oncology company dedicated to pioneering immunotherapies tailored for cancer treatment. At the forefront of its portfolio is nemvaleukin alfa, its lead product candidate designed to combat mucosal melanoma independently and in conjunction with pembrolizumab for platinum-resistant ovarian cancer. The company's research extends to leveraging nemvaleukin for the treatment of cutaneous melanoma and advanced solid tumors.
In addition to nemvaleukin alfa, Mural Oncology plc is advancing engineered interleukin-18 and tumor-targeted interleukin-12 programs. These initiatives represent the company's commitment to developing innovative immunotherapy solutions aimed at enhancing patient outcomes across various cancer types.
Established in 2017 and headquartered in Dublin, Ireland, Mural Oncology plc operates at the forefront of oncological research and development. Its strategic location in Dublin supports its efforts to collaborate with global partners and leverage Ireland's vibrant biopharmaceutical ecosystem.
Driven by a mission to transform cancer treatment paradigms, Mural Oncology plc continues to expand its therapeutic pipeline, emphasizing scientific innovation and rigorous clinical research. The company's initiatives underscore its dedication to addressing unmet medical needs in oncology and improving the lives of cancer patients worldwide.